Citations

Clear

4847 citation(s) found for "Tu, Eric".

Utilization of artificial intelligence (AI) scribes (AIS) by the hematology and oncology (HemOnc) workforce: Characterizing adoption patterns, barriers, and clinical gaps.
Correia, Guilherme Sacchi de Camargo, Tawfiq, Reema, Singhi, Eric K. , Rhinehart, Dena, Marrone, Kristen A., Badar, Talha, Jillella, Anand P., Gosain, Rahul , Gosain, Rohit , Flora, Douglas B., Moustafa, Magda, Manochakian, Rami , Tawfiq, Reema, Rhinehart, Dena P. , Warrier, Govind , Marrone, Kristen A., Badar, Talha , Flora, Douglas B.

Mayo Clinic

Journal of Clinical Oncology | May 28, 2026 | Volume: 44 | Issue: 16_suppl | Pages: No page available

10.1200/jco.2026.44.16_suppl.e13677 Get It

e13677 Background: The development of AI led to the emergence of tools such as AIS, which have been increasingly adopted in medicine. However, formal evaluation of barriers and clinical care gaps in HemOnc is limited, particularly regarding treatment plan complexities and toxicity documentation. Methods: Structured investigator-developed surveys about AIS availability, adoption, benefits, and challenges were developed on Qualtrics and approved by the IRB. HemOnc faculty physicians (FP), advanced practice providers (APP), and trainees (HOT) were surveyed between 11/14/25-1/16/26. Surveys were distributed in the USA via email, social media (on X), and ASCO myConnection. Descriptive statistics were used for analysis. Results: 132 participants responded to the survey: 55 FP (42%), 14 APP (11%), and 63 HOT (48%). 80% of them reported having AIS at their institutions, and 54% of those reported using these tools in their clinical practice. Among FP and APP, 72% practiced in academic settings, 14% in community, and 13% in hybrid centers. Among those not using AIS, identified barriers were issues with note formatting (56%), lack of training (25%), and concerns that the note content is incorrect or inadequate (25%). 60% are willing to use AIS if note formatting matched their preference, and 42% would try it if contents better reflected the patient encounter. Table 1 details the proportion of encounters using AIS, the portion of documentation it was used for, and the perceived challenges with these tools. Among AIS users, the average satisfaction score was 5.3 on a 7 point scale, corresponding to participants being somewhat satisfied. Participants agreed slightly that AIS had reduced their feeling of work-related burnout, with an average score of 3.6 on a 5 point scale. Overall, participants felt neutral about how well-suited AIS are for HemOnc, with an average score of 4.0 on a 7 point scale. Conclusions: Despite AIS being widely available, 46% of the surveyed HemOnc workforce do not use them in clinical practice. Those who do reported decreased time spent on documentation outside work hours and a slight reduction in the feeling of burnout. Formatting issues and record integration remain barriers, with substantial concerns about AIS not adequately describing HemOnc treatment plans. To bridge the last mile of integration into HemOnc, partnership between AIS developers and the clinical workforce is essential to meet clinical needs, while prioritizing patient safety and data privacy. FP + APP % HOT % Patient encounters where AIS is used 62 44 Used AIS for the subjective portion of note 68 96 Used AIS for the assessment/plan portions of note 40 25 AIS decreased the time on clinical documentation outside work hours 96 93 AIS note formatting needs improvement 68 57 Issues integrating AIS and outside records 46 71 AIS note contents about the plan are suboptimal 32 61
Patient-reported outcomes from the adjuvant ado-trastuzumab emtansine (T-DM1) for older patients with HER2+ breast cancer (ATOP) trial.
Ruddy, Kathryn Jean, Ginos, Brenda, Heiling, Hillary, Rogak, Lauren , Atanasov, Stafan S., Sinclair, Sarah, Fenton, Mary Anne, Muss, Hyman, Sinclair, Natalie, Hamilton, Erika P., Dang, Chau T., Faggen, Meredith, Lo, S., Mitchell, Sandra A., Winer, Eric P., Dueck, Amylou C., Ruddy, Kathryn J. , Heiling, Hillary , Sedrak, Mina S. , Atanasov, S., Sinclair, Sarah , Mortimer, Joanne , Fenton, Mary Anne , Sinclair, Natalie, Lo, Steve, Mitchell, Sandra A , Winer, Eric P. , Dueck, Amylou C. , Freedman, Rachel A.

Mayo Clinic

Journal of Clinical Oncology | May 27, 2026 | Volume: 44 | Issue: 16_suppl | Pages: 635-635

10.1200/jco.2026.44.16_suppl.635 Get It

635 Background: Prospective data on efficacy, quality of life, and treatment-related toxicities in older adults with breast cancer are limited. The ATOP trial (NCT03587740) evaluated T-DM1 in older adults and demonstrated favorable 5-year invasive disease-free survival. Here, we report patient-reported adverse events (AEs) and health-related quality of life (HRQOL) findings from ATOP. Methods: ATOP was a single-arm, phase II, multicenter study of adjuvant T-DM1 for those aged 60 with stage I-III HER2+ breast cancer. Protocol therapy included postoperative administration of T-DM1 (3.6 mg/kg) every 21 days for one year (17 cycles). PRO-CTCAE (assessing specific symptoms) and EQ-5D (a measure of HRQOL) surveys were administered electronically or on paper at baseline (pre-treatment), on Day 1 of each treatment cycle, and at a single 6–12-month post-treatment time point. Participants who responded to the baseline and at least one follow-up survey were included in the PRO analysis. EQ-5D changes from baseline were assessed using general linear mixed models. Summary statistics were used to assess PRO-CTCAE scores to evaluate which symptoms developed between baseline and 1 subsequent survey(s) and their severity. Results: Among the 111 patients enrolled on ATOP (median age=71, range 60-88 years), 98 responded to the baseline survey and 1 subsequent survey(s). 1435 surveys were returned that included at least one PRO-CTCAE response, and 1661 surveys were returned that included EQ-5D. The Table displays the % of participants who reported PRO-CTCAE symptoms that worsened from baseline to any severity level (scores >0) or to a severe level (scores ≥3). More than 60% of survey respondents reported new or increased dry mouth, fatigue, muscle aches, decreased appetite, nausea, pain, and/or numbness/tingling at some point during or after treatment, but these were usually not severe. EQ-5D scores did not change significantly from baseline at any time point. Conclusions: In this adjuvant trial for patients aged >60, participation rates for PRO data collection were high. Reassuringly, global HRQOL was not impacted by T-DM1, and though frequently reported, the vast majority of patient-reported symptoms were mild. Future analyses of this trial will focus on duration and predictors (clinical and biomarker-based) of severe AEs, agreement between patient-reported and clinician-reported AEs, and whether sharing PRO reports with clinicians impacted clinician-reported AE grades. Clinical trial information: NCT03587740 . Most common new or worsening symptoms reported via PRO-CTCAE in ATOP (n=95). Symptom % with score >0 n (%) with score 3+ Dry mouth 79% 26% Fatigue 71% 29% Muscle aches 69% 20% Decreased appetite 69% 12% Nausea 67% 6% Pain 66% 21% Numbness/tingling 65% 9% Blurry vision 60% 4% Mouth or throat sores 60% 5%
EA1181: Accuracy of pre-surgery MRI to predict pathologic complete response after taxane, trastuzumab, and pertuzumab (THP) in HER2-positive breast cancer.
Tung, NM, Zhao, Fengmin, Partridge, Savannah C., Wright, Jean, Recht, Abram, Weiss, Anna, Tjoe, Judy A., Feldman, Sheldon M. , Smith, Mary Lou , O'Sullivan, Ciara Catherine, Sardesai, Sagar D., Winer, Eric P., Partridge, Ann H., Carey, L, DeMichele, Angela, Tung, Nadine , Zhao, Fengmin , Partridge, Savannah C , Recht, Abram , Weiss, Anna, Tjoe, Judy A., Rocque, Gabrielle B. , O’Sullivan, Ciara C. , Sardesai, Sagar , Badve, Sunil , Winer, Eric P. , Miller, Kathy D. , Partridge, Ann H. , Carey, Lisa A. , Rahbar, Habib , DeMichele, Angela , Wolff, Antonio C.

Mayo Clinic

Journal of Clinical Oncology | May 27, 2026 | Volume: 44 | Issue: 16_suppl | Pages: 603-603

10.1200/jco.2026.44.16_suppl.603 Get It

603 Background: Accurate prediction of pathologic complete response (pCR) after preoperative therapy for HER2-positive (HER2+) breast cancer can help triage patients to immediate surgery vs additional preoperative therapy. Pre-surgery (i.e., after neoadjuvant therapy) imaging studies may help estimate the likelihood of pCR. In EA1181, patients (pts) with stage II-IIIA HER2+ breast cancer received four cycles of preoperative taxane, trastuzumab, and pertuzumab (THP×4). Pre-surgery imaging was required, though the specific imaging modality was not mandated. Here, we report the accuracy of pre-surgery breast MRI to predict pCR (ypT0/Tis, ypN0). Methods: Among 2,141 pts treated with THPx4, 1,378 had pre-surgery breast MRI and were representative of the overall cohort, although T3 tumors were more common (16% vs 9%). MRI reports were available for 1,351 pts; all reports were centrally reviewed and classified as radiologic complete response (rCR; no residual tumor enhancement and normalization of lymph nodes, if applicable) or radiologic residual disease (rRD). Reports with indeterminate radiologic response were independently reviewed by two study radiologists blinded to pathology outcomes. Among pts with rCR who had pathologic residual disease (pRD), we also assessed the extent of residual disease by residual cancer burden (RCB) score. Among pts with rRD who had a pCR, we determined the proportion who only had residual ductal carcinoma in situ (DCIS). Results: See Table. Conclusions: After neoadjuvant therapy, preoperative MRI accurately predicted pCR in 86% of patients with HER2+/ER− disease and may help identify patients who can proceed directly to surgery. MRI is insufficient to predict pCR for pts with HER2+/ER+ disease, as only 55% with complete response on MRI had a pCR at surgery. A pre-surgery MRI that indicated residual disease was accurate in 80% of pts with HER2+/ER+ disease, but in only 45% of pts with HER2+/ER- cancer. Accurately predicting residual disease after THPx4 allows for consideration of additional therapy that may increase the chance of pCR. Combining imaging like MRI with other biomarkers, such as tissue-based markers or circulating tumor DNA, may improve prediction of pCR and facilitate personalization of treatment decisions in HER2+ breast cancer. All pts with pre-surgery MRI (n=1351)pCR rate overall in this cohort = 47% MRI result Pathology pCR pRD rCR 70.6% (341/483) 29.4%(142/483) 78% had RCB1 rRD 34%(295/868) 21% of 295 had DCIS only 66.01% (573/868) ER- (n=589)*Overall pCR rate in ER- subset = 68% MRI result Pathology pCR pRD rCR 86.1% (205/238) 13.9% (33/238) 85% had RCB1 rRD 55.3% (194/351) 19% of 194 had only DCIS 44.7% (157/351) ER+ (n= 762)*Overall pCR rate in ER+ subset = 31% MRI result Pathology pCR pRD rCR 55.5% (136/245) 44.5% (109/245) 76% had RCB1 rRD 19.5% (101/517) 26% of 101 had only DCIS 80.5% (416/517)
Effect of a weight loss intervention (WLI) on quality of life (QOL) and symptoms in women with breast cancer: Results from the Breast Cancer Weight Loss (BWEL) trial.
Ligibel, Jennifer A. , Hershman, Dawn L., Dueck, A. C. , McCall, Linda, Ginos, Brenda, Weiss, Anna, Hahn, Olwen, Spears, Patricia, Paskett, Electra D., Hopkins, Judith O. , Frank, Elizabeth S., Bernstein, Vanessa , Stearns, Vered, White, Julia R., Wadden, Thomas, Winer, Eric P., Carey, L, Partridge, Ann H., Hershman, Dawn L. , Goodwin, Pamela J. , Paskett, Electra D. , Mayer, Erica L. , Stearns, Vered , White, Julia , Wadden, Thomas A., Winer, Eric P. , Carey, Lisa A. , Partridge, Ann H.

Mayo Clinic

Journal of Clinical Oncology | May 27, 2026 | Volume: 44 | Issue: 16_suppl | Pages: 12010-12010

10.1200/jco.2026.44.16_suppl.12010 Get It

12010 Background: BWEL (Alliance A011401; NCT02750826) is a Phase III trial that randomizes patients (pts) with stage II-III breast cancer and body mass index (BMI) ≥27 kg/m 2 1:1 to a 24-month (mo) lifestyle-based WLI + health education (HE) or HE alone. Here we report prespecified secondary outcomes of the impact of the WLI on patient-reported QOL and symptoms. Methods: The first 540 BWEL pts (randomized between 9/2016 and 7/2017) were included in this substudy that collected PROMIS 29 Profile 2.0 and Global Health scores at enrollment, 6 and 24 mos. Adjusting for baseline scores, mean physical function (predefined substudy primary outcome), global physical and mental health, fatigue and other scores were compared at 6 and 24 mos using analysis of covariance (ANCOVA). P-values <0.05 were considered significant. Positive differences in positive attributes (e.g., physical function) and negative differences in negative attributes (e.g., anxiety) represented better outcomes in the WLI arm. Results: At baseline, median BMI was 32.9 kg/m 2 (26.5 – 69.1), median age was 53 (25 - 78) years; 83.9% of pts were non-Hispanic White, 10.7% were Black and 5.9% were Hispanic. At 6 mos, the WLI (vs HE) arm had significantly better physical function (ANCOVA-based mean difference between arms 1.9 [95% CI 0.8, 3.0]; p<0.001), global physical health (2.0 [95% CI 0.9, 3.0]; p<0.001), global mental health (1.30 [95% CI 0.2, 2.4], p=0.03), social roles and activities (2.3 [95% CI 1.1, 3.6]; p<0.001), and fatigue (-1.7 [95% CI -3.1, -0.4], p=0.01) (Table). Improvements were generally maintained at 24 mos. Similar findings were seen in analyses using longitudinal mixed modeling. Conclusions: The BWEL WLI demonstrated QOL benefits for patients with breast cancer, resulting in significantly better physical function, global physical and mental health, and symptoms. Future analyses will evaluate which populations experienced the most benefit, as well as the relationships among QOL, symptoms, and weight loss. Support: U10CA180821, U10CA180882, UG1CA189823; U10CA180820; U10CA180868; U10CA180863, CCS 707213; U10CA180888; UG1CA189858; https://acknowledgments.alliancefound.org. Clinical trial information: NCT02750826 . Analysis of covariance-adjusted least squares means values at 6-mos adjusted for baseline scores. QOL/Symptom Attributes HE WLI Between arm difference (95% CI)* P value Physical Function 47.1 49.0 1.9 (0.8, 3.0) <0.001 Global Physical Health 46.2 48.1 2.0 (0.9, 3.0) <0.001 Global Mental Health 48.6 49.9 1.3 (0.2, 2.4) 0.03 Social Roles and Activities 52.7 55.0 2.3 (1.1, 3.6) <0.001 Anxiety 50.2 50.0 -0.2 (-1.6, 1.2) 0.77 Depression 47.5 47.5 -0.0 (11.2, 1.2) 0.96 Fatigue 50.6 48.9 -1.7 (-3.1, -0.4) 0.01 Sleep Disturbance 51.0 51.1 0.1 (-0.6, 0.8) 0.80 Pain Interference 51.3 50.3 -1.0 (-2.4, 0.4) 0.15 *Positive differences in positive attributes and negative differences in negative attributes favor WLI arm.
Decompression with or without Duraplasty for Chiari I and Syringomyelia
Limbrick, David D. , Shannon, Chevis N., Bayman, Emine O., Meehan, Thanda, Kallem, Marisa, Ackerman, Laurie L. , Adelson, P. David , Albert, Gregory, Aldana, Philipp R. , Alden, Tord D. , Anderson, Richard C. E. , Baird, Lissa C., Bauer, David, Bethel-Anderson, Tammy, Bierbrauer, Karin, Brockmeyer, Douglas L. , Chern, Joshua J. , Couture, Daniel, Daniels, David J., Dauser, Robert C., Durham, Susan, Ellenbogen, Richard G., Eskandari, Ramin, Gannon, Stephen R., Grant, Gerald A., Greene, Stephanie, Gross, Naina L. , Guillaume, Daniel J. (Daniel James), Hankinson, T., Heuer, Gregory, Iantosca, Mark, Iskandar, Bermans J. , Jackson, Eric M., Keating, Robert F., Kelly, Michael P., Kennedy, Elaine, Krieger, Mark D., Kulkarni, Abhaya V., Labuda, Rick, Leonard, Jeffrey R., Maher, Cormac O. , Mangano, Francesco T. , McComb, J. Gordon, McEvoy, Sean D., Niazi, Toba N., Oakes, Jerry, Olavarria, Greg, O’Neill, Brent R., Poppe, Dorothy, Ragheb, John, Reynolds, Lisa, Selden, Nathan R., Shah, Manish N., Smyth, Matthew D., Spears, Sandy, Stone, Scellig , Strahle, Jennifer M., Tamber, M, Tramelli, Gina, Tuite, Gerald F. , Vance, Haley, Wait, Scott D. , Wellons, John C. , Whitehead, WE, Yahanda, Alexander T., Yan, Yan, Dacey, Ralph G. , Park, Tae Sung, Torner, James C., Kelly, Michael P. , Torner, James C. , Dlouhy, Brian J , Iskandar, Bermans J , Yahanda, Alexander T , Kelly, Michael P , Limbrick, David D. , Bayman, Emine O. , Ahmed, Raheel , Albert, Gregory W. , Bierbrauer, Karin S. , Daniels, David J. , Ellenbogen, Richard G., Graupman, Patrick C. , Greenberg, Jacob K , Greenfield, Jeffrey P. , Guillaume, Daniel, Iantosca, Mark, Jackson, Eric M., Jallo, George I. , Johnston, James M. , Keating, Robert F., Kennedy, Elaine, Kulkarni, Abhaya V. , McComb, J. Gordon , McKinstry, Robert C. , Menezes, Arnold H. , Poppe, Dorothy , Ragheb, John , Reeves, Samuel, Reynolds, Lisa, Selden, Nathan R. W. , Shah, Manish N. , Shimony, Joshua S. , Strahle, Jennifer M. , Tamber, Mandeep S. , Tyler‐Kabara, Elizabeth C. , Vance, E. Haley, Yahanda, Alexander T. , Park, Tae Sung

Mayo Clinic

New England Journal of Medicine | May 27, 2026 | Volume: 394 | Issue: 20 | Pages: 2015-2025

10.1056/nejmoa2402821 | PMID 42202320 Get It

State Policy Variation and Telehealth Use by Oncology Specialists Treating Medicaid Patients
Vichare, Anushree , Luo, Qian (Eric), Khera, Nandita , Gandhi, Arpita, Shipman, Scott A., Erikson, Clese, Vichare, Anushree M. , Bodas, Mandar , Luo, Qian , Erikson, Clese

Mayo Clinic

Telemedicine and e-Health | May 27, 2026 | Volume: 32 | Issue: 9 | Pages: 970-974

10.1177/15305627261455444 | PMID 42202051 Get It

Telehealth may improve access to specialized oncology care for Medicaid beneficiaries with hematological malignancies who face geographic and financial barriers. During the COVID-19 public health emergency, telehealth use expanded rapidly, yet state policies governing telehealth coverage/payment parity varied. Evidence is limited on how these policy differences influenced oncology telehealth use for Medicaid patients. We conducted a cross-sectional analysis of 2020–2021 multistate Medicaid claims. Adult and pediatric oncology specialists were identified based on board certification data. Telehealth video visits were measured monthly at the extensive margin, defined as the proportion of specialists providing any telehealth, and the intensive margin, defined as average monthly telehealth visits among telehealth providing specialists. States were categorized by private insurance telehealth policy environment: coverage and payment parity, coverage parity only, or no or unspecified parity. Telehealth use increased sharply across all states in early 2020, rising from less than 1% of specialists before the pandemic to peak levels by April 2020. Specialists practicing in coverage and payment parity states demonstrated higher and more sustained telehealth use through 2021 compared with those in coverage only or no parity states. By December 2021, 15.1% of adult specialists in coverage and payment parity states provided telehealth, compared with 8.1% in coverage-only states and 7.8% in no-parity states. Pediatric specialists showed similar patterns, though overall telehealth use remained lower. Specialists in parity states also maintained higher monthly telehealth visit volumes over time. State-level coverage and payment parity policies may have been associated with greater and sustained telehealth provision by oncology specialists treating Medicaid beneficiaries with hematologic malignancies. Maintaining supportive telehealth policies may be essential for promoting equitable access to specialized cancer care and reducing disparities among underserved populations. These findings inform future telehealth policy decisions nationally statewide.
Lower Trapezius Transfer at the Time of Reverse Shoulder Arthroplasty with an Allograft-Prosthetic Composite Can Restore External Rotation
Sánchez‐Sotelo, Joaquín , Hart, Christopher M. , Weir, Tristan B. , Graden, Nathan , Gulzar, Musab , Elhassan, Bassem T. , Wagner, Eric, Elhassan, Bassem T. , Sanchez-Sotelo, J. , Weir, Tristan B. , Graden, Nathan R. , Wagner, Eric R.

Mayo Clinic

Journal of Bone and Joint Surgery | May 21, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.2106/jbjs.25.01692 | PMID 42166562 Get It

Background: The purpose of this study was to describe, and report the outcomes of, a surgical technique that combines reverse shoulder arthroplasty (RSA) using an allograft-prosthetic composite (APC) with a lower trapezius transfer (LTT) to the infraspinatus of the allograft extended with the inferior capsule. Methods: Between 2019 and 2023, 2 surgeons performed a total of 27 RSAs using an APC in conjunction with an LTT. Once the RSA APC reconstruction had been performed, cuff-capsule allograft tissue was passed posterior to the glenosphere and secured to the harvested lower trapezius. One shoulder was resected for periprosthetic joint infection; the remaining 26 shoulders were followed for a minimum of 2 years (mean, 2.7 years; range, 2 to 5 years). Results: The rate of revision or reoperation for humeral complications was 15% and included secondary bone grafting (2 shoulders), resection for infection (1 shoulder), and internal fixation of a periprosthetic fracture (1 shoulder). Other complications requiring surgery included hematoma treated with evacuation (2 shoulders), dislocation (1 shoulder), and glenosphere disassociation (1 shoulder). Preoperatively, 11 shoulders presented with pseudoparalysis, and the mean active elevation of the remaining 16 shoulders was 43°, with only 1 shoulder demonstrating >90° of active elevation. At the most recent follow-up, 3 shoulders were pseudoparalytic, 11 had <90° of active elevation, 8 had >90° of active elevation, and 3 had active elevation to 90°. The overall mean active elevation of the 25 shoulders that could be assessed was 79°. Preoperatively, only 4 (15%) of the 27 shoulders demonstrated active external rotation past neutral; at the most recent follow-up, 80% of surviving shoulders had active external rotation past neutral. Conclusions: LTT at the time of RSA using an APC has the potential to restore active external rotation in shoulders with proximal humeral bone loss and posterosuperior cuff deficiency. Level of Evidence: Therapeutic Level IV . See Instructions for Authors for a complete description of levels of evidence.
Comparative effectiveness of sulfonylureas on kidney outcomes in adults with type 2 diabetes and moderate cardiovascular risk: a target trial emulation
Sklepinski, Stacey , Ratzki-Leewing, Alexandria A , Herrin, Jeph, Swarna, Kavya Sindhu, Deng, Yihong, Neumiller, Joshua J, Galindo, R, Umpierrez, Guillermo E. , Ross, Joseph S, Mickelson, Mindy M, Umpierrez, Guillermo E. , Montori, Victor M , McCoy, Rozalina Grubina , SKLEPINSKI, STACEY , Ratzki-Leewing, Alexandria A , Herrin, Jeph , Swarna, Kavya, Deng, Yihong , Polley, Eric C. , Neumiller, Joshua J. , Galindo, Rodolfo J. , Ross, Joseph S. , Brito, Juan P. , Montori, Víctor M. , Mickelson, Mindy M , McCoy, Rozalina G.

Mayo Clinic

BMJ Open Diabetes Research & Care | May 21, 2026 | Volume: 14 | Issue: 3 | Pages: e005775

10.1136/bmjdrc-2025-005775 | PMID 42167878 Get It

Introduction To assess the within-class variation in kidney outcomes following initiation of sulfonylurea therapy. Research design and methods We used claims data of enrollees in commercial, Medicare Advantage, and traditional Medicare health plans between 2014 and 2021 to emulate a target trial including adults ≥21 years with type 2 diabetes at moderate cardiovascular risk to compare initiation of glimepiride, glipizide, or glyburide on the incidence of chronic kidney disease (CKD) stage 3 or worse, including initiation of kidney replacement therapy (primary outcome); secondary outcomes examined incident CKD stages 3-4, kidney failure (including kidney replacement therapy), all-cause mortality, and hypoglycemia requiring emergency department or hospital care. Random treatment assignment was emulated using propensity scores, estimated using the super learner ensemble method, and incorporated as inverse probability of treatment weights into proportional hazards models. Results The weighted study cohort included 295 092 individuals starting glimepiride (n=134 926), glipizide (n=145 984), and glyburide (n=14 182). One year after treatment initiation, stage 3 or worse CKD developed in 2.1% of patients in the glimepiride group, 2.2% in the glipizide group, and 1.8% in the glyburide group. Glyburide was associated with a lower risk of kidney complications compared with both glimepiride (HR 0.84, 95% CI 0.76 to 0.92) and glipizide (HR 0.81, 95% CI 0.73 to 0.89), despite a higher risk of severe hypoglycemia (HR 1.47, 95% CI 1.27 to 1.71 vs glipizide and HR 1.22, 95% CI 1.05 to 1.42 vs glimepiride). In contrast, the risk of kidney complications was modestly increased with glipizide compared with glimepiride use (HR 1.04, 95% CI 1.00 to 1.07). Conclusions Glyburide was associated with a modestly lower risk of kidney complications, despite a higher risk of hypoglycemia, while glipizide was associated with a higher risk of kidney complications. These hypothesis-generating findings suggest important within-class differences that warrant consideration in clinical decision-making and future research. Despite rigorous prespecified causal inference analytic methods, the risk of unmeasured confounding and bias by indication with the use of observational data remains. Trial registration number NCT05214573 .
Cost‐effectiveness of vorasidenib in treatment of isocitrate dehydrogenase–mutated low‐grade glioma
Kessel, Adam , Kim, H, Brown, P D, Lehrer, Eric J. , Laack, N., Mahajan, Anita, Yan, Elizabeth, Schultz, Sydney E., Kizilbash, Dr Sani, Neth, Bryan, Sener, Ugur, Waddle, Mark, Breen, William G. , Kowalchuk, Roman O. , Neth, Bryan J. , Kessel, Adam C , Brown, Paul D , Kizilbash, Sani, Neth, Byran J. , Sener, Ugur , Waddle, Mark R , Mahajan, Anita, Kizilbash, Sani H. , Sener, Uğur

Mayo Clinic

Cancer | May 20, 2026 | Volume: 132 | Issue: 11 | Pages: No page available

10.1002/cncr.70463 | PMID 42159181 Get It

Abstract Background Vorasidenib is Food and Drug Administration‐approved for treatment of grade 2 isocitrate dehydrogenase (IDH)–mutant gliomas and has demonstrated a benefit in progression‐free survival compared to a placebo. This study assessed the cost‐effectiveness of this treatment strategy compared to standard treatment: observation or chemoradiation (CRT). Methods The authors used an integrated Markov model to compare quality‐adjusted life‐years (QALY) gained and cost‐effectiveness of patients with IDH‐mutated low‐grade glioma (LGG) treated with vorasidenib, observation, or CRT. Outcomes were expressed as incremental cost‐effectiveness ratios (ICERs) per QALY gained. Treatment is considered cost‐effective if it meets the commonly accepted willingness‐to‐pay threshold of $100,000 per QALY gained. Results Based on model parameters, vorasidenib demonstrated an ICER of $356,756 per QALY when compared to CRT. When compared to observation, vorasidenib demonstrated an improved ICER of $215,191 per QALY. On one‐way sensitivity analysis compared to observation, median cost of vorasidenib and median overall survival were most likely to affect ICER with only marginal changes on analysis of other model factors. For ICER to become ≤$100,000 compared to observation, the cost of vorasidenib would need to drop to below $14,072 monthly or have a median survival gain of at least 11.9 years. The probabilistic sensitivity analysis demonstrated that vorasidenib was favored in none of 5000 Monte Carlo iterations. Conclusion Using the best available data, the current price of vorasidenib does not meet commonly accepted cost‐effectiveness thresholds in treatment of IDH‐mutated LGGs.
Optimizing Radiography Utilization: Multidisciplinary Expert Consensus Recommendations Endorsed by the Society of Academic Bone Radiologists, Society of Skeletal Radiology, American Society of Emergency Radiology,
Rilland, Eddy D. Zandee van , Fayad, Laura M. , Link, Thomas M. , Davis, Kirkland W. , Wu, Jim S. , Chang, Eric Y. , Chow, Lawrence C. , Desai, Shaun C., Fritz, Jan, Gorbachova, Tetyana , Gray, Mingyang L., Gross, Joel A. , Ha, Patrick K., Halle, Tyler R. , Hall, M. Kennedy, Lee, Mark A. , Mann, Edana D. , Obey, Mitchel R. , Osgood, Greg M., Patel, Zara M. , Rendon, Juan M. , Sabbatini, Amber K. , Tannoury, Chadi , Yu, Joseph S. , Boutin, Robert D. , Zandee van Rilland, Eddy D , Brown, Ian P , Chang, Eric Y , Chow, Lawrence C , Gatz, J David , Garner, Hillary W , Gorbachova, Tetyana , Guermazi, Ali , Halle, Tyler R , Hanna, Tarek N , Kornblith, Aaron E , Lopez-Ben, Robert R , Mann, Edana D , Moore, Christopher L. , Obey, Mitchel R , Patel, Zara , Raja, Ali S , Rendon, Juan M , Sabbatini, Amber K , Tannoury, Chadi , Yu, Joseph S , Boutin, Robert D , Link, Thomas M , Desai, Shaun C. , Fritz, Jan , Garner, Hillary W. , Gray, Mingyang Liu , Hall, M. Kennedy , Osgood, Greg Michael

Mayo Clinic

Radiology | May 19, 2026 | Volume: 319 | Issue: 2 | Pages: No page available

10.1148/radiol.252309 | PMID 42153836 Get It

Expert consensus recommendations from 21 academic centers were established for appropriate radiography utilization at 12 potentially low-yield anatomic sites through a multidisciplinary process endorsed by six major American medical societies.